Open Payments

VALLEY CHILDRENS HOSPITAL

Type
Teaching hospital
Where
MADERA, CA
Medicare CCN
053300
Received
$170,309 in 38 records, 2019 ($4,331 general, $165,977 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment10$4,331
2019Research payment28$165,977

By company

CompanyRecordsAmountYears
VERTEX PHARMACEUTICALS INCORPORATED4$133,5992019
Eisai Inc.3$25,6442019
PFIZER INC.3$2,3972019
E.R. Squibb & Sons, L.L.C.1$1,5002019
Abbott Laboratories3$1,2552019
Incyte Corporation8$1,1032019
AstraZeneca Pharmaceuticals LP2$1,0002019
Stryker Corporation1$7092019
Insulet Corporation1$5002019
LIFESCAN, INC.1$5002019
Lilly USA, LLC1$5002019
COLOPLAST CORP1$5002019
Ipsen Biopharmaceuticals, Inc1$5002019
Merck Sharp & Dohme LLC4$2852019
Novo Nordisk AS2$1922019
Masimo Corporation2$1212019

By nature of payment

NatureRecordsAmount
Research payment28$165,977
Space rental or facility fees (teaching hospital only)5$2,500
Compensation for services other than consulting, including serving as faculty or as a speaker at a v2$1,000
Gift1$709
Education2$121

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Stryker Corporation$709GiftCash or cash equivalentNONE Device, NONE2019
2019-12-31Masimo Corporation$118EducationIn-kind items and servicesEMMA and ISA Device, Devices2019
2019-12-31Masimo Corporation$2EducationIn-kind items and servicesSET and rainbow SET Device, Devices2019
2019-12-10Novo Nordisk AS$117Research paymentIn-kind items and servicesSogroya Biological, Growth HormoneNN8640-42632019
2019-12-10Novo Nordisk AS$75Research paymentIn-kind items and servicesSogroya Biological, Growth HormoneNN8640-42632019
2019-12-09Incyte Corporation$20Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-12-09Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-12-09Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-11-16Ipsen Biopharmaceuticals, Inc$500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDYSPORT Drug, Neurology2019
2019-10-10Abbott Laboratories$500Research paymentCash or cash equivalentAMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart FailureClosure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study2019
2019-10-08COLOPLAST CORP$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentSPEEDICATH Device, CONTINENCE2019
2019-10-08Incyte Corporation$21Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-10-08Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-10-08Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-10-08Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-08-29Incyte Corporation$1,000Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2019
2019-08-02Merck Sharp & Dohme LLC$97Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or2019
2019-07-25Abbott Laboratories$500Research paymentCash or cash equivalentAMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart FailureClosure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study2019
2019-06-27E.R. Squibb & Sons, L.L.C.$1,500Research paymentCash or cash equivalentOPDIVO Biological, OncologyPhase IIA Nivo in HL Pediatric nivo bv2019
2019-06-18Eisai Inc.$500Research paymentCash or cash equivalentFycompa Drug, NeurologyA Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Pat2019
2019-06-18Eisai Inc.$200Research paymentCash or cash equivalentFycompa Drug, NeurologyA Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Pat2019
2019-06-13Abbott Laboratories$255Research paymentCash or cash equivalentAMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart FailureClosure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study2019
2019-05-23Eisai Inc.$24,944Research paymentCash or cash equivalentFycompa Drug, NeurologyA Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Pat2019
2019-05-02Insulet Corporation$500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOmnipod Device, Insulin Pump2019
2019-05-01PFIZER INC.$1,776Research paymentIn-kind items and servicesELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASEA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2019
2019-05-01PFIZER INC.$414Research paymentIn-kind items and servicesELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASEA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2019
2019-05-01PFIZER INC.$207Research paymentIn-kind items and servicesELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASEA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2019
2019-04-28AstraZeneca Pharmaceuticals LP$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentFASENRA Drug, Respiratory2019
2019-03-06LIFESCAN, INC.$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentOneTouch Device, Diabetes Testing2019
2019-02-25Lilly USA, LLC$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-02-22Merck Sharp & Dohme LLC$8Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or2019
2019-01-31AstraZeneca Pharmaceuticals LP$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentFASENRA Drug, Respiratory2019
2019-01-25VERTEX PHARMACEUTICALS INCORPORATED$2,156Research paymentCash or cash equivalentORKAMBI Drug, CYSTIC FIBROSISA Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety of Orkambi in US Patients Who Com2019
2019-01-10Merck Sharp & Dohme LLC$97Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or2019
2019-01-07Merck Sharp & Dohme LLC$82Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or2019
2019-01-01VERTEX PHARMACEUTICALS INCORPORATED$92,289Research paymentCash or cash equivalentA Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy2019
2019-01-01VERTEX PHARMACEUTICALS INCORPORATED$29,373Research paymentCash or cash equivalentA Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and2019
2019-01-01VERTEX PHARMACEUTICALS INCORPORATED$9,780Research paymentCash or cash equivalentA Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Madera CountyMadera city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Madera, CA, county Madera County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Madera, CA
County
Madera County, CA
State
California
Population B0100367,831160,94039,287,377
Population, 2020 census P166,224156,25539,538,223
Median age B0100230.434.637.9
Under 18 B0100130.8%27.1%22.0%
65 and over B010019.6%14.4%15.7%
Households B1100117,52645,37913,548,091
Foreign born B0500225.6%20.1%27.0%
Median household income B19013$63,933$76,627$99,122
Median family income B19113$67,479$83,389$113,346
Per capita income B19301$24,200$30,077$49,513
Poverty rate B1700125.6%19.2%12.0%
Unemployment rate B2302512.6%10.1%6.6%
Civilian labor force B2302529,99769,01220,068,466
Mean commute (minutes) B0801325.727.928.7
Bachelor's degree or higher B1500310.9%17.9%37.1%
Housing units B2500118,56251,01514,644,735
Owner-occupied B2500354.7%67.5%55.9%
Renters B2500345.3%32.5%44.1%
Median home value B25077$359,900$393,200$734,700
Median gross rent B25064$1,353$1,390$2,036
White, not Hispanic B0300212.2%29.9%33.8%
Black B030022.9%2.4%5.2%
Hispanic or Latino B0300281.1%60.9%40.2%
Asian B030021.3%2.4%15.3%
American Indian and Alaska Native B030020.1%0.4%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.